 | ||||||||||||||||||||||||||||||||||
|
|
|
Transplant Timing and Diseases TreatedSeveral important factors affecting patient survival outcomes of a hematopoietic cell transplant include:
Additional factors affecting transplant outcomes include the patient's age and co-morbidities, urgency of the need for a transplant and availability of a well-matched donor or cord blood unit. On this page:Transplant timingTransplant outcomes are affected by performing an unrelated donor or cord blood transplant at an appropriate time during the disease (usually remission) and according to the patient’s health.The patient's treatment plan may indicate the need for an immediate transplant. Or, another treatment may be performed initially, with a plan to move to transplant quickly, if the need arises. The Recommended Timing for Transplant Consultation (marrow.org) guidelines were developed and published jointly by the National Marrow Donor Program (NMDP) and American Society of Blood and Marrow Transplantation (ASBMT). These guidelines are based on current clinical practice and the medical literature, as well as comprehensive evidence-based reviews [1].
Hematopoietic cell transplantation is a potential life-saving treatment option for some patients. However, one of the critical factors in improved outcomes is appropriate timing of the transplant. These guidelines:
 Diseases treatable by a hematopoietic cell transplantDue to long-term experience, ongoing studies and advances in transplantation:
Below is a list of diseases for which autologous or allogeneic hematopoietic cell transplantation may be a treatment. The list includes diagnoses for which transplantation is a standard treatment as well as diagnoses for which transplantation is a newer option. When information about a disease is available on marrow.org, it is linked to Table 1: Disease Specific Information and Outcomes. Leukemias and lymphomas, including:
Multiple myeloma and other plasma cell disorders Severe aplastic anemia and other marrow failure states, including:
SCID and other inherited immune system disorders, including:
Hemoglobinopathies, including:
Hurler's syndrome and other inherited metabolic disorders, including:
Myelodysplastic and myeloproliferative disorders (MDS), including:
Familial erythrophagocytic lymphohistiocytosis and other histiocytic disorders Other malignancies Table 1. Disease Specific Information and Outcomes
References
|
|
 E-mail a Friend Print this PagePre-transplant Factors Affecting Outcomes
Transplant Terms
Hematopoietic cell transplant (HCT) is also referred to as:
A transplant may also be described by cell source:
Hematopoietic cells are also referred to as:
Medical Professional
|
||||||||||||||||||||||||||||||
